Lymphoma Treatment Market Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Test Type (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, and Others), Drug (Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid,

Lymphoma Treatment Market Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Test Type (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, and Others), Drug (Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, and Others), and Region 2024-2032

The global lymphoma treatment market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.

The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, test type and drug.

Breakup by Type:

• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma

Breakup by Test Type:

• Chemotherapy
• Radiation Therapy
• mmunotherapy
• Targeted Therapy
• Biologic Therapy
• Others

Breakup by Drug:

• Adcetris
• Rituxan
• Opdivo
• mbruvica
• Keytruda
• Revlimid
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

• How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global lymphoma treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the drug?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global lymphoma treatment market and who are the key players?
• What is the degree of competition in the industry?